Neurol. praxi. 2022;23(3):217-220 | DOI: 10.36290/neu.2022.033

Breastfeeding and multiple sclerosis

MUDr. Eva Meluzínová
Neurologická klinika FN Motol a 2. LF UK, Praha

Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease affecting the brain and spinal cord. Most often the disease begins between the ages of 20-30 and occurs three times as often in women. Treatment is initiated early, preferably after the first symptom of the disease. In patients of childbearing age, it is advisable to choose a drug that is safe after conception. The period of pregnancy has a favourable effect on the course of the disease, with a decrease in activity in most cases. In stable patients, therapy is discontinued. If patients have unplanned pregnancy and the disease is not stable, therapy with certain drugs can be continued. This communication gives an overview of the drugs that can be given not only during pregnancy but also during lactation. The procedures used in the care of women after childbirth and during lactation are mentioned. Stabilized patients are assured of safe therapy during this time and can continue breastfeeding for 4-6 months. Other drugs from both the first and escalation lines do not yet have a proven safety profile during pregnancy or lactation and are therefore not mentioned in the article.

Keywords: multiple sclerosis, pregnancy, breastfeeding, interferon­‑beta, glatiramer acetate, exclusive breastfeeding, relapse, methylprednisolone.

Received: June 1, 2022; Revised: June 1, 2022; Accepted: June 1, 2022; Prepublished online: June 1, 2022; Published: June 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Meluzínová E. Breastfeeding and multiple sclerosis. Neurol. praxi. 2022;23(3):217-220. doi: 10.36290/neu.2022.033.
Download citation

References

  1. Almas S, Vance J, Baker T, Hale T. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int. 2016;2016:6527458. doi: 10.1155/2016/6527458. Epub 2016 Feb 4. PMID: 26966579; PMCID: PMC4757692. Go to original source... Go to PubMed...
  2. Boz C, Terzi M, Zengin Karahan S, et al. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. Mult Scler. 2018;24(9):1205-1211. doi: 10.1177/1352458517717806. Epub 2017 Jun 26. PMID: 28649909. Go to original source... Go to PubMed...
  3. Ciplea AI, Langer­‑Gould A, Stahl A, et al. Safety of potential breast milk exposure to IFN­‑β or glatiramer acetate: One­‑year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 202020;7(4):e757. doi: 10.1212/NXI.0000000000000757. PMID: 32434802; PMCID: PMC7251509. Go to original source... Go to PubMed...
  4. Ciplea AI, et al. COBRA draft manuscript. 2021.
  5. Cooper SD, Felkins K, Baker TE, Hale TW. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31(2):237-9. doi: 10.1177/0890334415570970. Epub 2015 Feb 17. PMID: 25691380. Go to original source... Go to PubMed...
  6. Hellwig K, Geissbuehler Y, Sabidó M. Data from the European Interferon Beta Pregnancy Registry and Population Based Registries in Finland and Sweden. Presented at: 34th Congress of the European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS). October 10-12, 2018 | Berlin, Germany. P1753. Go to original source...
  7. Hellwig K, Rockhoff M, Herbstritt S, et al. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA Neurol. 2015; 72: 1132-1138. Go to original source... Go to PubMed...
  8. Hradilek P, Meluzinova E, Zapletalova O, et al. Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic. Mult Scler Relat Disord. 2021;59:103391 doi: 10.1016/j.msard.2021.103391. Epub ahead of print. PMID: 35240415 Go to original source... Go to PubMed...
  9. Paavilainen T, Kurki T, Parkkola R, et al. Eur Magnetic resonance imaging of the brain used to detect early post­‑partum activation of multiple sclerosis. J Neurol. 2007;14(11):1216-21. doi: 10.1111/j.1468-1331.2007.01927.x. Epub 2007 Aug 28.PMID: 17727663 Clinical Trial. Go to original source... Go to PubMed...
  10. Krejsek J, Andrýs C, Krčmová I. Imunologie člověka. Hradec Králové: Garamon 2016:495.
  11. Lyons K­‑E, Ryan A, Dempsey E, Ross P, Stanton C. Breast Milk, a Source of Beneficial Microbes and Associated Benefits for Infant Health Nutrients. 2020;12(4):1039. Go to original source... Go to PubMed...
  12. Švihovec J, et al. Farmakologie. Grada Publishing, a. s., 2018.
  13. Vukusic S, Hutchinson M, Hours M, et al; Pregnancy In Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post­‑partum relapse. Brain. 2004;127. (pt 6):1353-1360. doi:10.1093/brain/awh152). Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.